ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis

Br J Haematol. 2016 Nov;175(3):534-536. doi: 10.1111/bjh.13865. Epub 2015 Dec 2.

Affiliations

¹ Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. [email protected].
² Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
³ Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
⁴ Division of Cytogenetics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

PMID: 26628266
DOI: 10.1111/bjh.13865

No abstract available

MeSH terms

Adult
Aged
Aged, 80 and over
Humans
Mastocytosis, Systemic / genetics*
Mastocytosis, Systemic / mortality
Middle Aged
Mutation*
Proto-Oncogene Proteins c-cbl / genetics*
Proto-Oncogene Proteins c-cbl / metabolism
Repressor Proteins / genetics*
Repressor Proteins / metabolism
Survival Analysis

Substances

ASXL1 protein, human
Repressor Proteins
Proto-Oncogene Proteins c-cbl
CBL protein, human